Alpine Immune Sciences, Inc. Price & Performance (ALPN)

The FDA’s approval of Amgen’s UPLIZNA for IgG4-related disease is set to reshape the rare autoimmune segment. New therapies like UPLIZNA are expected to accelerate market expansion, with projections indicating robust growth from $170 million in 2024 as improved treatment options enter the market.1

Alpine Select’s latest update underscores Idorsia’s successful debt restructuring and regulatory wins, positioning the Swiss biotech for potential growth. Meanwhile, global equity indices remain under pressure from geopolitical tensions and renewed tariffs, with consumer confidence at historic lows and risk assets declining across major markets.2

Vertex Pharmaceuticals’ stock has surged 20% year-to-date, bucking a broader market downturn. The company’s leadership in cystic fibrosis therapy, new FDA approvals, and a diversified clinical pipeline are fueling optimism, as competitors grapple with patent cliffs and slower growth, supporting a bullish outlook for Vertex in 2025.3